



Results of Annual General Meeting

27 November 2024

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company"), is pleased to advise that at the Annual General Meeting held today at 2.00pm (AEST), shareholders of the Company passed all Resolutions as set out in the Notice of Meeting dated 28 October 2024 by way of poll.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act a summary of the proxy votes received and poll results on each Resolution is attached.

– ENDS –

This announcement has been approved by the Company Secretary.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma's lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information, please contact:

Haley Chartres
Media Relations
haley@hck.digital

Peter McLennan
Investor Relations
investors@ltrpharma.com

Disclosure of Proxy Votes

LTR Pharma Limited
Annual General Meeting
Wednesday, 27 November 2024



AUTOMIC
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	2,402,818	2,190,516 91.16%	129,460 5.39%	0	82,842 3.45%	8,650,425 98.53%	129,460 1.47%	0	-
2 Re-election of Julian Chick as Director	P	55,221,844	55,129,002 99.83%	10,000 0.02%	90,000	82,842 0.15%	61,588,911 99.98%	10,000 0.02%	90,000	Carried
3 Ratification of Prior Issue of Fully Paid Ordinary Shares	P	55,179,844	54,941,307 99.57%	155,695 0.28%	132,000	82,842 0.15%	61,401,216 99.75%	155,695 0.25%	132,000	Carried
4 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	55,299,844	54,313,947 98.22%	903,055 1.63%	12,000	82,842 0.15%	60,773,856 98.54%	903,055 1.46%	12,000	Carried
5 Approval of Issue of Options to Lee Rodne, Director of the Company	P	2,631,306	1,957,004 74.37%	541,460 20.58%	2,118,788	132,842 5.05%	8,466,913 93.99%	541,460 6.01%	2,118,788	Carried
6 Approval of Issue of Options to Julian Chick, Director of the Company	P	55,304,840	54,630,538 98.78%	541,460 0.98%	7,004	132,842 0.24%	61,140,447 99.12%	541,460 0.88%	7,004	Carried
7 Approval of Issue of Options to Maja McGuire, Director of the Company	P	55,069,348	54,395,046 98.78%	541,460 0.98%	7,004	132,842 0.24%	60,904,955 99.12%	541,460 0.88%	7,004	Carried

